Assessing efficacy in early-phase cancer prevention trials: the case of oral premalignancy.
Szabo
Eva
E
Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, MD 20892, USA. szaboe@mail.nih.gov
D000236:Adenoma / Q000517:prevention & control*; D015415:Biomarkers / Q000032:analysis; D002277:Carcinoma / Q000517:prevention & control*; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D055088:Early Detection of Cancer; D006801:Humans; D009062:Mouth Neoplasms / Q000517:prevention & control*; D009369:Neoplasms / Q000175:diagnosis / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D015415:Biomarkers